Evidence map›Paper›PMID 40956059›Full record

ArticleACS applied materials & interfaces2025

Bioactive Light-Responsive Au Nanohybrids for Reactive Oxygen Species-Driven Macrophage Reprogramming.

Ting-Yu Cheng, Li-Chan Chang, Li-Xing Yang, Sz-Syuan Wu, Yu-Cheng Chin, Ya-Jyun Chen, Zi-Chun Chia, Wen-Pin Su, Chih-Chia Huang

Abstract read
In one paragraph

Article in ACS applied materials & interfaces, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Phase-Dependent MoSInternational journal of molecular sciences · 2026
    Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Ting-Yu ChengDepartment of Photonics, National Cheng Kung University, Tainan 701, Taiwan.ORCID 0000-0003-2632-4073
Li-Chan ChangInstitute of Clinical Medicine, College of Medicine, National Cheng Kung University, Tainan 704, Taiwan.ORCID 0000-0002-9953-5800
Li-Xing YangDepartment of Photonics, National Cheng Kung University, Tainan 701, Taiwan.
Sz-Syuan WuDepartment of Photonics, National Cheng Kung University, Tainan 701, Taiwan.
Yu-Cheng ChinDepartment of Photonics, National Cheng Kung University, Tainan 701, Taiwan.ORCID 0000-0002-0302-7925
Ya-Jyun ChenDepartment of Photonics, National Cheng Kung University, Tainan 701, Taiwan.
Zi-Chun ChiaDepartment of Photonics, National Cheng Kung University, Tainan 701, Taiwan.
Wen-Pin SuInstitute of Clinical Medicine, College of Medicine, National Cheng Kung University, Tainan 704, Taiwan.ORCID 0000-0003-0863-203X
Chih-Chia HuangDepartment of Photonics, National Cheng Kung University, Tainan 701, Taiwan.ORCID 0000-0002-9486-8665

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Optical modulation of immune responses via nanomaterials has emerged as a promising approach in cancer immunotherapy, but challenges in achieving precise activation with minimal phototoxicity persist. In this study, we developed a galactose-functionalized Au-S (2ATP)/polyaniline (PANI)-based glycopolymer nanoparticle (Au/2ATP@PGlyco NP) to enable multivalent galactose-based biostimulation of M2-like macrophages and hot electron/hole-elicited reactive oxygen species (ROS) generation for synergistic macrophage reprogramming. The 2ATP@PANI-based shell not only facilitated light-driven charge transfer to enhance

Indexed as

Cellular ReprogrammingGoldMacrophagesMetal NanoparticlesReactive Oxygen SpeciesAniline CompoundsAnimalsApoptosisCell Line, TumorGalactoseHumansLightMiceAniline CompoundsGalactoseGoldReactive Oxygen Speciesbioactive nanohybridsimmunotherapylight-responsive nanoparticlesmacrophage reprogrammingphototherapy

Identifiers

PMID40956059
PMCPMC12492335

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.